Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02678013
Recruitment Status : Active, not recruiting
First Posted : February 9, 2016
Last Update Posted : February 23, 2016
Sponsor:
Information provided by (Responsible Party):
Ming Kuang, Sun Yat-sen University

Brief Summary:
Hepatocellular carcinoma (HCC) is the fifth most common and the third leading cause of cancer-related death worldwide. Recurrence of tumor within the liver remnant is common, with a reported 5-year recurrence rate of 70%. Repeat hepatectomy is an effective treatment for intrahepatic HCC but with a small proportion of resection rate because of the poor functional liver reserve and postoperative complications. Radiofrequency ablation(RFA) is becoming the main effective treatment for small HCC (≤5.0cm). The efficacy of RFA for recurrent HCC has been reported to be comparable to those achieved by surgery with minimal, but higher local recurrence rate after RFA. It has been reported that immunotherapy in patients who underwent curative treatment for HCC, adjuvant immunotherapy with activated CIK cells increased recurrence-free and overall survival. But there is little evidence for adjuvant immunotherapy of recurrence HCC. Cytotoxic T lymphocytes(CTL), a kind of effective T cells that specific recognizing and killing antigen targeted cells through cloning amplification after receiving antigen information from antigen presented cell and playing key role to clear cancerous cells. So our hypothesis is that RFA combined with immunotherapy (Highly-purified CTL) is superior to RFA for recurrent HCC. The aim of this prospective study is to compare the outcome of RFA combined with immunotherapy (Highly-purified CTL) with RFA for small recurrent HCC after partial hepatectomy.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Procedure: RFA Procedure: RFA+highly-purified CTL Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 210 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Radiofrequency Ablation Combined With Highly-purified CTL vs. Radiofrequency Ablation Alone for Recurrent HCC
Study Start Date : February 2016
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2022

Arm Intervention/treatment
Experimental: Radiofrequency ablation(RFA)
RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
Procedure: RFA
Radiofrequency ablation(RFA)for small recurrent HCC

Active Comparator: RFA+CTL
RFA was performed the same as RFA Arm.Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective patients who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Patients in the immunotherapy group received 5*10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. They were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving RFA, followed by 6-9 treatments during 6 months to 2 years after receiving RFA.
Procedure: RFA+highly-purified CTL
Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC




Primary Outcome Measures :
  1. Recurrence-free survival [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 5 years ]
  2. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 [ Time Frame: 1 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. age 18-75 years;
  2. recurrence of HCC 12 months after initial hepatectomy;
  3. no other treatment received except for the initial hepatectomy;
  4. single tumor≤5.0cm in diameter; or 2-3 lesions each≤3.0cm;
  5. lesions visible on ultrasound and with an acceptable and safe path between the lesion and the skin as shown on ultrasound;
  6. no severe coagulation disorders (prothrombin activity<40% or a platelet count<40,000/mm3);
  7. Eastern Co-operative Oncology Group performance(ECOG) status 0-1.

Exclusion Criteria:

  1. Pregnant women, breastfeeding women or plan pregnancy for the future 2 years;
  2. The presence of vascular invasion or extrahepatic spread onimaging;
  3. Usage of strong immunosuppressive agents such as corticosteroids, cyclosporine A within six months or longer;
  4. HIV antibody or HCV antibody positive;
  5. Immunodeficiency diseases or autoimmune diseases (such as rheumatoid arthritis, Buerger's disease, multiple sclerosis and type 1 diabetes);
  6. Suffering with cancers (except skin cancer, prostate cancer or cervical carcinoma in situ) at the enrolling time or 5 years before;
  7. Suffering with other organ failure;
  8. Suffering with severe mental illness;
  9. Drug addiction (including alcohol) for 1 year before the enrolling time;
  10. Participate in other Clinical trials within three months prior to 3 months before the enrolling time;
  11. Other researchers believe that the patient is not fit for inclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02678013


Locations
Layout table for location information
China, Guangdong
Zhen-Wei Peng
Guangzhou, Guangdong, China, 510080
Sponsors and Collaborators
Ming Kuang
Investigators
Layout table for investigator information
Principal Investigator: Ming Kuang, Ph.D. First Affiliated Hospital, Sun Yat-Sen University
Publications:
Layout table for additonal information
Responsible Party: Ming Kuang, Ph.D.,M.D., Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT02678013    
Other Study ID Numbers: HCC 004
First Posted: February 9, 2016    Key Record Dates
Last Update Posted: February 23, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases